As the week comes to an end, it’s time to start thinking about weekend plans. Whether it’s tidying up, taking a trip to see a college campus, or catching up on reading, there are plenty of ways to relax and enjoy the days off. With colder weather approaching, it’s a good time to bundle up and get some fresh air outside. Consider buying a new sweater or planning a holiday getaway. It’s also a great time to reach out to someone special and make lasting memories. Whatever you choose to do, remember to stay safe and have a wonderful time.
In recent news, European regulators have recommended the approval of an Alzheimer’s therapy from Eisai and Biogen, known as Leqembi. This decision comes after a previous rejection due to concerns over the drug’s benefits and risks. However, after a re-examination process, the committee concluded that the benefits of Leqembi outweigh the risks for certain patients. This recommendation will now go to the European Commission for final approval.
On another front, Eli Lilly has filed a lawsuit against the U.S. Health Resources and Services Administration (HRSA) over changes to reimbursement for hospitals under the 340B Drug Discount Program. The company’s plan to pay cash directly to 340B hospitals was rejected by the HRSA, leading to legal action. This is the second lawsuit from a drug company against the HRSA regarding payment terms. Participation in the 340B program is crucial for drugmakers to receive funds from government health insurance programs.
As we look ahead to the weekend, it’s important to stay informed about developments in the pharmaceutical industry. Keep an eye out for updates on these stories and more in the coming days. Stay safe, stay warm, and enjoy the weekend ahead.
